Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download APIFINY® Prostate Cancer Risk Assessment Lower Risk Higher
Transcript
Information for Healthcare Professionals The only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer. ® APIFINY Prostate Cancer 0 Lower Risk 59 Higher Risk 100 Risk Assessment Copyright © 2008-2016, Armune BioScience, Inc. The only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer. What is APIFINY®? • APIFINY® is a cancer specific blood test that measures biological markers known to be associated with an immune system response to prostate cancer. • APIFINY measures eight autoantibodies released by the immune system in response to the presence of prostate cancer.1 • APIFINY autoantibodies were discovered by research conducted at the University of Michigan under the direction of Arul Chinnaiyan, MD, PhD.2 • APIFINY does NOT rely on PSA or a calculation based on various forms of PSA. • APIFINY is offered as a laboratory service available only to healthcare providers to enable improved risk assessment for the presence of prostate cancer in patients presenting with a PSA >2.5 ng/ml or other high risk factors. • APIFINY is offered by Armune BioScience in its CLIA regulated laboratory located in Ann Arbor, MI. The test is used for clinical purposes. It has not been cleared or approved by the FDA. When should I order APIFINY? • APIFINY may be used in men who have an elevated PSA (>2.5 ng/ml) and are considering a prostate biopsy. Why should I order APIFINY? • APIFINY measures cancer specific biological markers that may provide you with additional insight to support a clinical decision. • In most cases, you already have the patient’s age, PSA level, DRE result, and personal and family health history. • Order APIFINY when additional, unique biological information may help to make a more informed clinical decision. 1. Translational Oncology, 2015; 8, 106-111 2. New England Journal of Medicine, 2005; 353:1224-1235 ® APIFINY Prostate Cancer 0 Lower Risk 59 Higher Risk 100 Risk Assessment How do I interpret an APIFINY Score? APIFINY, combined with existing patient health information and your clinical experience, may aid in the assessment of prostate cancer risk. Interpretation of Results for Lower Risk Patients: “In the most recent peer-reviewed published study on APIFINY,1 approximately 9 out of 10 men like you, with a score of less than 59, were cancer free.” Interpretation of Results for Higher Risk Patients: “In the most recent peer-reviewed published study on APIFINY,1 approximately 1 out of 3 men like you, with a score of 59 or above, had prostate cancer. You may be at higher risk.” Order APIFINY Test Kits today! ® ® APIFINY Prostate Cancer 0 Lower Risk 59 Higher Risk 100 Risk Assessment The only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer. Armune BioScience, Inc. 401 West Morgan Road Ann Arbor, MI 48108 Toll Free Helpline: 844-427-6863 www.armune.com APIFINY® is performed in the Armune BioScience high-complexity CLIA laboratory. MM-004 Rev.05 03/16
